GHK-Cu complex reduced bleomycin-induced pulmonary fibrosis in mice by inhibiting inflammation (TNF-α, IL-6), collagen deposition, and epithelial-mesenchymal transition via the TGFβ1/Smad2/3 pathway.
Blocked EMT + TGF-βGHK-Cu inhibited both epithelial-mesenchymal transition and TGFβ1/Smad2/3 signaling — the core drivers of pulmonary fibrosis
What the researchers found
GHK-Cu inhibited pulmonary fibrosis by reducing TNF-α/IL-6, collagen deposition, and EMT progression through suppression of TGFβ1/Smad2/3 signaling and NF-κB, with Nrf2 pathway activation.
Why it matters
IPF kills ~40,000 Americans annually with only two approved drugs (pirfenidone, nintedanib) that slow but don't stop disease. GHK-Cu is a naturally occurring peptide with a strong safety profile that targets the core fibrotic pathway.
The numbers in context
Doses: 0.2, 2, 20 ug/g/day IP q.o.d.; reduced TNF-alpha, IL-6, MPO; decreased collagen; reversed MMP-9/TIMP-1; modulated Nrf2, NF-kB, TGFb1/Smad2/3
How the study worked
Mouse bleomycin-induced pulmonary fibrosis model; GHK-Cu at 0.2, 2, and 20 µg/g/day IP on alternate days for 21 days; histology, BALF cytokine analysis, collagen quantification, EMT markers (α-SMA, fibronectin), Western blot for NF-κB, Nrf2, TGFβ1/Smad2/3.
Who was studied
C57BL/6j mice with bleomycin-induced pulmonary fibrosis
What this study cannot tell us
Bleomycin mouse model is acute fibrosis (not the slow progressive fibrosis of human IPF); IP injection route differs from potential clinical routes; long-term outcomes not assessed.
How to read the evidence
Moderate — dose-response animal study with comprehensive pathway analysis, but acute model may not represent chronic human IPF.
When this study was published
Published in 2020; GHK-Cu for lung disease is a novel application of a well-studied peptide.
The bigger picture
GHK-Cu is already used in skincare for its regenerative properties. This study suggests it could also address one of pulmonology's most challenging diseases by targeting the same TGF-β pathway that drives skin and lung scarring.
Questions still open
- Could inhaled GHK-Cu deliver the peptide directly to fibrotic lungs?
- How does GHK-Cu compare to pirfenidone or nintedanib in this model?
- Would GHK-Cu work in established fibrosis, or only prevention?
Common questions
What is GHK-Cu?
How does lung fibrosis form?
Read the original research
Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways.
Life sciences, 241, 117139
Citation
Ma, Wen-Hui; Li, Meng; Ma, Hai-Feng; Li, Wei; Liu, Li; Yin, Yan; Zhou, Xiao-Ming; Hou, Gang. (2020). Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways.. Life sciences, 241, 117139. https://doi.org/10.1016/j.lfs.2019.117139